Investigational Drug Information for Tipifarnib
✉ Email this page to a colleague
What is the development status for investigational drug Tipifarnib?
Tipifarnib is an investigational drug.
There have been 85 clinical trials for Tipifarnib.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 1999.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, and Leukemia, Myeloid, Acute. The leading clinical trial sponsors are National Cancer Institute (NCI), Kura Oncology, Inc., and Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Summary for Tipifarnib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 5,655 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 1,056 |
| Clinical Trial Progress | Phase 3 (1999-11-01) |
| Vendors | 52 |
Recent Clinical Trials for Tipifarnib
| Title | Sponsor | Phase |
|---|---|---|
| Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer | Kura Oncology, Inc. | Phase 1 |
| Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN | Jiangbin Hospital Affiliated to Jiangsu University | Phase 2 |
| Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN | Jiangning Hospital Affiliated to Nanjing Medical University | Phase 2 |
Clinical Trial Summary for Tipifarnib
Top disease conditions for Tipifarnib
Top clinical trial sponsors for Tipifarnib
US Patents for Tipifarnib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
